S&P Futures
4,043.00 -41.25 (-1.01%) Dow Futures
33,794.00 -252.00 (-0.74%) Nasdaq Futures
12,053.50 -168.75 (-1.38%) Russell 2000 Futures
1,899.40 -20.10 (-1.05%) Crude Oil
79.68 0.00 (0.00%) Gold
1,940.20 -5.40 (-0.28%)
Cyteir Therapeutics, Inc. (CYT)
Chart Events
Performance Outlook
| Previous Close | 1.5900 |
| Open | 1.5600 |
| Bid | 0.0000 x 1800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 1.5600 - 1.7050 |
| 52 Week Range | 1.1300 - 7.3120 |
| Volume | |
| Avg. Volume | 102,954 |
| Market Cap | 60.423M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 0.31 |
| EPS (TTM) | 5.4500 |
| Earnings Date | Mar 16, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYT
Related Research
- Cyteir Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/25/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
- Business Wire
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
LEXINGTON, Mass., January 19, 2023--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer. The prioritization follows encouraging preliminary clinical activity in a small number of patients observed in the Phase 1 dose escalation cohort with CYT-0851 in combination with capecitabine in advan
- Business Wire
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
LEXINGTON, Mass., November 07, 2022--Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on recent operational highlights.
- Simply Wall St.
Great news for Cyteir Therapeutics, Inc. (NASDAQ:CYT): Insiders acquired stock in large numbers last year
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
